SANUWAVE Q4 2025: Record Revenue, Record Systems, and an Industry Shockwave
The wound care microcap we pitched in August just reported. Here's where it stands.
To read our full disclaimer, click here.
I wrote up SANUWAVE (SNWV) in August at $35.
It’s $17.50 today.
Before getting into the update, that’s where this starts - down 50% from the original call.
However, the business itself had its best year ever.
So why is the stock cut in half? And more importantly, is the thesis from here still intact?
The numbers
Revenue: $44.1M, up 35%
Adjusted EBITDA: $13.6M, up from $7.2M
Gross margin: 77.1%
Systems sold: 624 (vs 374 in 2024)
Consumables: $25.5M, 58% of revenue, up 27%
Q4 revenue: $13.4M (record), 255 systems placed
Worth flagging: FY revenue of $44.1M came in well below the $48–50M management guided to when I originally wrote this up.
That’s a miss, not a beat.
What broke
CMS cut reimbursement for skin substitutes and allografts by 90–95% in 2025 and started auditing aggressively. Some providers got hit with nine-figure clawbacks. Management called it a grenade in a fish pond.
UltraMIST wasn’t the target - its reimbursement code actually got a small bump for 2026. But a chunk of SANUWAVE’s customer base ran skin subs alongside UltraMIST, and when skin subs blew up, those customers did too. Some pulled back on volume. Some closed.
The damage shows up in consumables, which is the number that matters in a razor-blade model. Full year consumables +27%. Q4 consumables +10.6%. That’s a sharp deceleration. And 168 active systems were discontinued in Q4 alone, about 13% of the installed base.
Net active systems still grew - 1,236 to 1,292 - but only because they placed 255 new ones on top of the churn. That’s running hard to move a little.
What I got wrong
No point pretending otherwise:
I underwrote 50%+ growth as sustainable. 2026 guidance is now 16–25%. Different business.
I expected the debt paid off by year-end 2025. It was refinanced, not eliminated - ~$21M still on the balance sheet.
I didn’t model an industry-adjacent reimbursement shock. Nobody did, but that’s not an excuse, it’s a lesson.
What’s genuinely better
A few things cut the other way and deserve credit:
Reseller channel. 32% of Q4 revenue, up from 26% in Q3. Former skin-sub distributors picking up UltraMIST because it has a clean reimbursement path. Higher operating margin because SANUWAVE doesn’t carry the sales cost. This wasn’t in the original thesis.
Debt cost. Refinanced with JP Morgan. Interest expense dropped from $2.7M in Q4 2024 to $603K in Q4 2025.
Manufacturing costs stepping down starting Q1 2026.
New customer formation. Management’s “baby elephants” - small new wound care groups emerging from the dissolution of old ones, actively seeking UltraMIST. Early, but real.
Where I land
The business is demonstrably stronger than a year ago on revenue, profitability, balance sheet, and distribution.
The growth trajectory I underwrote is not the growth trajectory I’m getting.
Those are both true.
What I don’t think is true: that the stock being down 50% means the pick was wrong.
The business didn’t fall apart. The industry around it did, and SNWV got caught in the downdraft despite its own reimbursement code being fine. That’s a real outcome, not a rationalization - but it also doesn’t erase the fact that I underwrote growth that isn’t showing up.
EV/EBITDA lands somewhere between ~9x on basic shares and ~19x fully loaded. The truth is in between. Either way, it's no longer the layup it was on the original thesis math.
Three things that decide whether this works from here:
Q1 consumables. Did the churn bottom in Q4 or is it still bleeding? Most important data point.
Reseller channel recurring pull-through. One quarter of strong reseller placements is a data point. Two quarters of recurring consumable orders behind them is a trend.
H2 2026 acceleration. Q1 guidance is +3–10%. Full year is +16–25%. That implies a big back-half pickup. If it doesn’t materialize, the deceleration is structural, not transitional.
Updating again after that print.
Thanks for reading,
Nico
Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute financial, investment, or other professional advice. The opinions expressed here are those of the author and do not necessarily reflect the views of The Clinical Edge. Investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. The author may or may not hold positions in the stocks or other financial instruments mentioned. Always do your own research or consult with a qualified financial advisor before making any investment decisions. To read our full disclaimer, click here.